临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 84-80-0

Vitamin K1

中文名称:维生素 K1
CAS号:84-80-0
分子式: C31H46O2 分子量: 450.70
产品形式: 2-methyl-1,4-naphthoquinones
研发状态: Recruiting
研发用途: Osteo Arthritis Knee
研究机构: Tufts University; University of North Carolina Chapel Hill; Tufts Medical Center
研发日期: September 20 2023
研发阶段: Not Applicable
Vitamin K1 (Phyllohydroquinone, Phylloquinone, Phytomenadione, Phytonadione), made by plants, is a major type of dietary vitamin K, which is well-known for its role in blood clotting. Vitamin K1 is directly involved in photosynthesis.

CAS: 847499-27-8

Delanzomib (CEP-18770)

中文名称:地兰佐米
CAS号:847499-27-8
分子式: C21H28BN3O5 分子量: 413.28
产品形式: free base
研发状态: Completed
研发用途: Multiple Myeloma
研究机构: Teva Branded Pharmaceutical Products R&D Inc.
研发日期: August 3 2011
研发阶段: Phase 1 : Phase 2
Delanzomib (CEP-18770) is an orally active inhibitor of the chymotrypsin-like activity of proteasome with IC50 of 3.8 nM, with only marginal inhibition of the tryptic and peptidylglutamyl activities of the proteosome. Phase 1/2.

CAS: 84680-54-6

Enalaprilat Dihydrate

中文名称:依那普利那二水
CAS号:84680-54-6
分子式: C18H24N2O5.2H2O 分子量: 348.40
产品形式: Dihydrate
研发状态: Active not recruiting
研发用途: Healthy Volunteers
研究机构: University of Michigan
研发日期: April 1 2017
研发阶段: Phase 4
Enalaprilat (MK-422) is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 1.94 nM.

CAS: 84625-61-6

Itraconazole (R 51211)

中文名称: 伊曲康唑
CAS号:84625-61-6
分子式: C35H38Cl2N8O4 分子量: 705.65
产品形式: free base
研发状态: Not yet recruiting
研发用途: Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Carcinoma
研究机构: VA Office of Research and Development; Durham VA Health Care System; VA Palo Alto Health Care System; Portland VA Medical Center; VA Puget Sound Health Care System; Michael E. DeBakey VA Medical Center; VA Boston Healthcare System
研发日期: May 1 2024
研发阶段: Phase 2
Itraconazole (R 51211) is a relatively potent inhibitor of CYP3A4 with IC50 of 6.1 nM, used as a triazole antifungal agent. Itraconazole is a potent antagonist of the Hedgehog (Hh) signaling pathway. Itraconazole suppresses the growth of glioblastoma through induction of autophagy.

CAS: 84611-23-4

Erdosteine

中文名称:厄多司坦
CAS号:84611-23-4
分子式: C8H11NO4S2 分子量: 249.31
产品形式: free base
研发状态: Unknown status
研发用途: Chronic Obstructive Pulmonary Disease (COPD)
研究机构: Edmond Pharma
研发日期: Aug-09
研发阶段: Phase 3
Erdosteine (KW-9144,RV 144) is a mucolytic which is used in treatment of excessive viscous mucus. Erdosteine inhibits lipopolysaccharide (LPS)-induced NF-κB activation.

CAS: 845959-50-4

Mitoquinone (MitoQ10) mesylate

中文名称:米托蒽醌甲磺酸盐
CAS号:845959-50-4
分子式: C38H47O7PS 分子量: 678.81
产品形式: mesylate
研发状态: Not yet recruiting
研发用途: Ulcerative Colitis
研究机构: University of Edinburgh; The Jon Moulton Charity Trust; MitoQ
研发日期: Sep-22
研发阶段: Phase 2
Mitoquinone mesylate (MitoQ, MitoQ10, Mitoubiquinone) is a TPP-based, mitochondria-targeted antioxidant that blocks H2O2-induced intracellular ROS responses and protects against oxidative damage. This product is a waxy solid.